To test the hypothesis that neural mechanisms evoked by unilateral pulmonary artery occlusion (UPAO) affect the release of atrial natriuretic peptides (ANP) from the heart, hemodynamics and levels of plasma ANP and cyclic guanosine monophosphate (c-GMP) were studied in 11 patients with lung cancer. The UPAO induced a significant rise in heart rate by 5.3 percent, increased mean pulmonary artery pressure by 31 percent without affecting right atrial pressure, and decreased plasma ANP levels in the coronary sinus by 17.4 percent (p<0.05) from 202.5 ± 27.1 pg/ml to 167.2 ± 27.4 pg/ml. Atropine sulfate (0.04 mg/kg) injection increased the heart rate by 38.2 percent (p<0.01), reduced the stroke volume index by 25.1 percent, decreased coronary sinus ANP levels from 198.5 ± 16.4 pg/ml to 124.8 ± 19.6 pg/ml (p<0.01), and decreased coronary sinus plasma c-GMP levels from A rial natriuretic peptides (ANP) are cardiac peptides with diuretic, natriuretic, and vasorelaxant effects that are released into the circulation from the heart.1 2 Atrial stretch is a major stimulus for ANP secretion and elevated plasma levels have been found in patients with congestive heart failure,3 systemic hypertension,4 and pulmonary hypertension.5-7
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Other studies have determined that activation of cardiopulmonary receptors by acute hypoxia and pulmonary hypertension is a powerful stimulus for ANP release that is attenuated by vagotomy.23824 4.6 ± 0.5 pmol/ml to 3.1 ± 0.4 pmol/mI (p<0.05). After atropine pretreatment, UPAO containing cancer to occlude the artery and measure pulmonary artery pressure, pulmonary artery wedge pressure, right atrial pressure, and cardiac output. A 5-F Sones catheter (Hanaco Medical, Tokyo) was positioned in the coronary sinus to sample coronary sinus blood via the right internal jugular vein. Correct positioning of the coronary sinus catheter was confirmed by fluoroscopy. A polyethylene catheter was inserted via the femoral artery into the aorta to measure arterial pressure and sample arterial blood while a second catheter was positioned in the femoral vein to sample venous blood. Blood samples were withdrawn simultaneously from the cannulas. Aortic pressure, right atrial pressure, pulmonary artery pressure, and pulmonary artery wedge pressure were recorded using pressure transducers (Statham P23Db) referenced to the midchest level. Cardiac output was measured by thermodilution using a cardiac output computer (model 9520-A, American Edwards Laboratory). Each cardiac output value represents the average of at least three measurements. Pulmonary vascular resistance, cardiac, and stroke volume indices were calculated according to the following respective equations: pulmonary vascular resistance index= (mean pulmonary artery pressure-pulmonary artery wedge pressure)/cardiac indexX80; cardiac index=cardiac output/body surface area; stroke volume index=cardiac index/heart rate. The arterial Po2 was measured with a gasoxymeter (ABL 2, Radiometer).
and at 15 and 60 min after deflation, hemodynamic measurements were made and blood was sampled. Ninety minutes after deflation, atropine sulfate (0.04 mg/kg) was injected via the femoral vein catheter and the protocol was repeated.
Chromatography and Measurements of Immunoreactive ANP and c-GMP
Gel permeation chromatography (GPC) was performed essentially as previously described.26 GPC was performed using a fractionating column (Sephadex G-75) (2X25 cm, Pharmacia, Tokyo). Acidified 0.2-ml samples were loaded directly onto the column and eluted with 0.5 M acetic acid at a flow rate of 5 ml/h at 4°C. Elution positions were determined using a peptide molecular weight calibration kit and synthetic a-, d-, and y-ANP. Samples were radioimmunoassayed for ANP before and after fractionation by GPC. The concentrations of c-GMP were measured using an 1251-labeled radioimmunoassay.
Statistical Analyses
All values are presented as the mean + SE. Statistical analysis was performed by analysis of variance followed by Duncan's multiple range test. Changes from control values in each unilateral pulmonary artery occlusion were compared using Student's t test. Statistical significance was accepted at any level of p<0.05.
Protocol
Following control hemodynamic measurements and blood sampling, the pulmonary artery was coronary sinus blood (4.7 ± 0.9 pmol/ml) were significantly (p<0.02) higher than in the pulmonary artery (3.4 ± 0.7 pmol/ml) and aorta (3.5 ± 0.7 pmol/ ml) but not in the vein (Table 1) . Control hemodynamics are shown in Table 2 . Effect of UPAO After UPAO, mean pulmonary artery pressure and pulmonary vascular resistance index increased (Table 2). Heart rate also increased from 73.5 ± 4.1 mm Hg to 77.4±4.9 mm Hg (p<0.05). There was no change in right atrial pressure, pulmonary artery wedge pressure, mean aortic pressure, or cardiac index. The arterial Po2 did not change significantly (Table 2) .
Plasma ANP levels in the coronary sinus decreased from 202.5±27.1 pg/ml to 167.2±27.4 pg/ml (p<0.05) after 15 min of UPAO and returned to control levels at 60 min after deflation (Table 1) . Plasma ANP levels in the pulmonary artery, aorta, and femoral vein did not decline significantly during or after UPAO. Cyclic GMP levels in the coronary sinus did not change during UPAO; however, they decreased from 4.7±0.9 pmol/ml to 3.6±0.6 pmol/ml at 15 min after UPAO (p<0.01). There was no significant change in c-GMP concentration in the pulmonary artery, aorta, or femoral vein.
Effects of Atropine
After atropine sulfate injection, the heart rate increased from 75.0 ± 4.9 beats/min to 104.6 ± 5.9 beats/min (p<0.01), and the stroke volume index decreased (Table 2) . Right atrial pressure, pulmonary artery pressure, pulmonary artery wedge pressure, mean aortic pressure, total pulmonary vascular resistance index, and arterial Po2 did not change after atropine injection.
Plasma ANP levels in the coronary sinus decreased from 198.7 ± 16.4 pg/ml to 124.8 ± 19.6 pg/ml (p<0.01) and c-GMP levels in the coronary sinus decreased from 4.6 ±0.5 pmol/ml to 3.1± 0.4 pmol/ml (p<0.05) after atropine injection (Table 1) . Neither ANP nor c-GMP levels in the pulmonary artery, aorta, or femoral vein changed significantly. The plasma level of c-GMP in the femoral vein was significantly higher than in the coronary sinus, pulmonary artery, or aorta.
Effect of UPAO After Atropine Injection
Mean pulmonary artery pressure was increased significantly by UPAO (Table 2 ). The total pulmonary vascular resistance index increased at 15 min of CHEST / 106 /5/ NOVEMBER, 1994 1383 UPAO. The heart rate decreased from 104.6 ± 5.9 mm Hg to 101.7 ±5.8 mm Hg (p<0.05). The UPAO did not induce any change in right atrial pressure, pulmonary artery pressure, pulmonary artery wedge pressure, mean aortic pressure, or stroke volume index.
Plasma AN P levels in the coronary sinus increased from 124.8 ± 19.6 pg/ml to 168.2 ± 24.6 pg/ml (p<0.05) during UPAO and returned to the preocclusion level within 60 min after deflation. The ANP levels in the pulmonary artery, aorta, and femoral vein did not change during or after UPAO. Cyclic GMP levels in the plasma of the coronary sinus, pulmonary artery, aorta, and femoral vein did not change significantly during or after UPAO. Molecular Forms of ANP Using GPC, elution profiles of ANP in the plasma of the coronary sinus before UPAO revealed three major peaks of immunoreactivity coeluting with a-, A-, and y-ANP. Peak immunoreactivity coeluting with a-and y-ANP decreased and f,-ANP disappeared during UPAO. The preocclusion elution profiles were restored at 15 min after deflation. After Before atropine atropine administration, peaks of immunoreactivity coelution with A-and y-ANP disappeared and the major peak was attributed solely to a-ANP. The UPAO induced either no change in the elution profile or the appearance of y-ANP associated with an increase in a-ANP peak (Fig 1) . DISCUSSION The principal findings in the present study were that UPAO nervous system, it becomes important to learn how the afferent and efferent pathways or central regulatory system affect the ANP axis. A complex maneuver, UPAO not only increases pulmonary artery and right ventricular pressures contralateral to the balloon, but also unloads the pulmonary artery ipsilaterally. It is difficult to explain the obtained results by postulating a single reflex mechanism, such as the Bainbridge reflex or cardiopulmonary baroreflex, particularly for the afferent pathway. Baertschi et a124 reported that activation of pulmonary stretch receptors by acute hypoxia and pulmonary hypertension stimulates ANP release and that this response is attenuated by vagotomy. In UPAO, pulmonary stretch receptors may also be involved in the reflex axis that modulates ANP release; however, this is only one of several possible mechanisms. The efferent mechanism of ANP release is controversial. Although we did not measure plasma norepinephrine levels, relative activation of the sympathetic nervous system during UPAO by direct sympathetic activation or by vagal withdrawal was manifested as an increase in heart rate during occlusion in the present study. Multiple factors may explain the observed decrements in baseline ANP levels and changes of elution profiles when muscarinic receptors were blocked. In explaining this, it may be difficult to rule out the possible roles of decreased atrial stretch due to decreased amplitude of atrial V-waves or decreased pulsatility, or dilution of ANP by increased coronary blood flow. However, the presence of tonic or baseline control of ANP secretion via vagal nerve must be considered in any proposed mechanism. Baertschi et a124 suggested that a neural reflex of pulmonary artery origin mediates approximately 50 percent of the ANP response to hypoxia in addition to conventional release mechanisms such as atrial stretch and pulsatility. Given that vagal nerves play a role in the tonic control of ANP secretion, our results indicated the presence of tonic stimulatory action on ANP secretion via the parasympathetic nervous system. This result agrees with the results of Antunes-Rodrigues et a129 who showed that unilateral right vagotomy reduced resting levels of plasma ANP in conscious rats. In contrast, Phillips et a122 suggested that parasympathetic control of ANP secretion is present and that the intact afferent vagus nerve exerts a tonic inhibition of atrial and plasma ANP secretion. We cannot explain the discrepancy between our findings and those of Phillips et al except to note that they performed bilateral vagotomy in anesthetized animals.
The mechanism by which the plasma ANP level is increased in the coronary sinus by UPAO after pretreatment with atropine is complicted. Although it would be predicted that attenuation of the ANP response to adrenergic stimulation by UPAO would be exaggerated when muscarinic receptors are blocked, no increase in heart rate or decrease in plasma ANP level was observed in the present study. The only plausible explanation for this is that the overwhelming increase in a-adrenergic tone compared with f3-adrenergic stimulation persisted after abolishment of efferent vagal tone, thereby increasing ANP release. In support of this hypothesis is the report by Jiao et al'6 that stimulation of central sympathetic nervous system in the lower brain stem stimulates potently the secretion of cardiac ANP. Upon withdrawal of vagal tone, stimulation of sympathetic efferent nerves may increase ANP secretion from the heart by an a-adrenergic mechanism.
In contrast to reports that ANP is released in response to a chronic increase in pulmonary artery pressure that modulates pulmonary vascular tone in patients with pulmonary hypertension,5'7 the present study did not show any change in the pulmonary artery plasma ANP level. The present study is limited by the fact that UPAO was sustained for only 15 min. Such a short duration of increase in pulmonary artery pressure may not be sufficient to augment ANP secretion as reported in studies showing increased plasma ANP levels in animal experiments6 or in patients with chronic pulmonary hypertension.5-7 Since it is impossible to sustain UPAO for longer periods of time in humans, it remains unknown whether this reflex control of ANP secretion has important clinical significance.
Cyclic-GMP is an intracellular second messenger of ANP and leaks into the systemic circulation.31 In the present study, although coronary sinus c-GMP levels were not affected by UPAO, we observed a significant decrease in the ANP concentration after atropine injection; this may reflect parallel changes on ANP levels. Tsutamoto et a132 reported that ANP was consumed while c-GMP was produced in the pulmonary circulation in patients with heart failure. The lack of a significant difference in either the ANP or c-GMP level between the pulmonary artery and aorta, as compared with the study of Tsutamoto et al, may be due to differences in the patient populations.
Peripheral plasma levels of c-GMP are not controlled by the autonomic nervous system, since high levels of femoral venous c-GMP, compared with those in the aorta, were consistently observed irrespective of UPAO or atropine injection. In summary, UPAO induced a decrease in plasma ANP levels and changes in the chromatographic elution profiles probably through a reflex mechanism. Lowering of the basal plasma ANP level in the coronary sinus during muscarinic blockage is consistent with vagal stimulation of ANP secretion from the heart.
